AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33977415 — intervention group
Group type: COMPARATOR
Intervention: Matched Italian population
Number of subjects: 205
Study 33977415 — intervention group
Group type: COMPARATOR
Intervention: Matched Finnish population
Number of subjects: 205
Study 33977686 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal ergospirometry
Number of subjects: 20
Study 33978191 — intervention group
Group type: EXPERIMENTAL
Intervention: CUN-BAE index
Number of subjects: 54
Study 33978519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Apnea, Daytime Sleepiness, Comorbidities, and Depression
Number of subjects: 198
Study 33978593 — intervention group
Group type: EXPERIMENTAL
Intervention: iMedA (adaptive digital intervention delivered via a mobile app)
Number of subjects: 0
Study 33978598 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual overdose response service (telephone-based)
Number of subjects: 15
Study 33978600 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-blockers
Number of subjects: 0
Study 33978600 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 inhibitors
Number of subjects: 0
Study 33978600 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK-inhibitors
Number of subjects: 0
Study 33978600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of treatment after achieving remission
Number of subjects: 0
Study 33978600 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective suppression of inflammation
Number of subjects: 0
Study 33978600 — intervention group
Group type: EXPERIMENTAL
Intervention: More sensitive measurements of radiographic progression
Number of subjects: 0
Study 33979100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with oxaliplatin and capecitabine followed by chemoradiotherapy
Number of subjects: 34
Study 33979178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifileucel (autologous tumor-infiltrating lymphocyte therapy) with a nonmyeloablative lymphodepletion regimen and up to six doses of high-dose interleukin-2.
Number of subjects: 66
Study 33979178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifileucel in primary refractory to anti-PD-1 or PD-L1 therapy subset.
Number of subjects: 66
Study 33979183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Behavioral Interventions
Number of subjects: 0
Study 33979183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33979314 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-34a + miR-210
Number of subjects: 91
Study 33979314 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-122 + miR-210
Number of subjects: 91
Study 33979314 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-34a + miR-122
Number of subjects: 91
Study 33979653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated RT (IMRT)
Number of subjects: 178
Study 33979653 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive-Scattering Proton Therapy (PSPT)
Number of subjects: 178
Study 33979653 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-Based Analyses (VBAs)
Number of subjects: 178
Study 33979653 — intervention group
Group type: EXPERIMENTAL
Intervention: PICA and connectograms
Number of subjects: 178
Study 33980224 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT program (QI intervention)
Number of subjects: 35
Study 33980232 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sedation with oral administration of ketamine and midazolam
Number of subjects: 152
Study 33980232 — intervention group
Group type: COMPARATOR
Intervention: Protective stabilization
Number of subjects: 152
Study 33980287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerliponase alfa
Number of subjects: 8
Study 33980287 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 8
Study 33980522 — intervention group
Group type: EXPERIMENTAL
Intervention: Translocator protein (TSPO) positron emission tomography neuroimaging preoperatively and postoperatively
Number of subjects: 30
Study 33980528 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Pupil Index (NPi) assessment
Number of subjects: 420
Study 33980528 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 420
Study 33980575 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasopasem manganese (AVA) given once before tumor irradiation and for 4 days after radiation
Number of subjects: 0
Study 33980575 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasopasem manganese (AVA)
Number of subjects: 0
Study 33980575 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose per fraction radiation
Number of subjects: 0
Study 33980575 — intervention group
Group type: COMPARATOR
Intervention: Conditional overexpression of catalase in tumors
Number of subjects: 0
Study 33980605 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microvascular disease (diabetic retinopathy, kidney disease, or CAN)
Number of subjects: 239
Study 33980605 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced microvascular disease (moderate to severe albuminuria or eGFR <60 mL/min/1.73 m)
Number of subjects: 239
Study 33980831 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab monotherapy
Number of subjects: 0
Study 33980895 — intervention group
Group type: EXPERIMENTAL
Intervention: VR perceptual learning games (DartBoard and Halloween) with depth cue scaffolding conditions.
Number of subjects: 20
Study 33980941 — intervention group
Group type: EXPERIMENTAL
Intervention: KRYPTOR assay
Number of subjects: 88
Study 33980941 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA assay
Number of subjects: 88
Study 33980941 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA assay
Number of subjects: 88
Study 33980941 — intervention group
Group type: EXPERIMENTAL
Intervention: KRYPTOR and LIA
Number of subjects: 88
Study 33980941 — intervention group
Group type: COMPARATOR
Intervention: ELISA
Number of subjects: 88
Study 33981160 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial epidural SP-102 injection (10 mg dexamethasone sodium phosphate)
Number of subjects: 0
Study 33981160 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat epidural SP-102 injection (10 mg dexamethasone sodium phosphate)
Number of subjects: 0
Study 33981160 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and repeat SP-102 injections
Number of subjects: 0
Study 33981279 — intervention group
Group type: EXPERIMENTAL
Intervention: BeatWalk application (individualized musical stimulation for gait rehabilitation)
Number of subjects: 45
Study 33981279 — intervention group
Group type: EXPERIMENTAL
Intervention: BeatWalk application
Number of subjects: 45
Study 33981389 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic chewing gum (n=20)
Number of subjects: 40
Study 33981389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 33981732 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score
Number of subjects: 0
Study 33981732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Risk Factors
Number of subjects: 0
Study 33981943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine Milk Fat Globule Membrane and Lactoferrin in infant formula
Number of subjects: 0
Study 33981943 — intervention group
Group type: COMPARATOR
Intervention: Control group (cow-milk-based infant formula without MFGM and LF)
Number of subjects: 0
Study 33981997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed intervention
Number of subjects: 0
Study 33981997 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed intervention
Number of subjects: 0
Study 33981997 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal depressive symptoms
Number of subjects: 1869
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to antiretroviral therapy (ART)
Number of subjects: 1869
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression (VS)
Number of subjects: 1869
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1869
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect effect of depressive symptoms on VS via ART adherence
Number of subjects: 1869
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct effect of depressive symptoms on VS
Number of subjects: 1869
Study 33982083 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of depressive symptoms on VS
Number of subjects: 1869
Study 33982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Erythroferrone (ERFE)
Number of subjects: 297
Study 33982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 297
Study 33982118 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 297
Study 33982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-to-EPO ratio
Number of subjects: 297
Study 33982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ERFE
Number of subjects: 297
Study 33982118 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-to-EPO ratio and EPO
Number of subjects: 297
Study 33982128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration ≤9.9 ng/mL
Number of subjects: 40
Study 33982128 — intervention group
Group type: COMPARATOR
Intervention: Serum 25(OH)D concentration >9.9 ng/mL
Number of subjects: 40
Study 33982128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration
Number of subjects: 40
Study 33982376 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg, multiple oral doses on days 1-4)
Number of subjects: 9
Study 33982376 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (500 mg, multiple oral doses on days 11-17)
Number of subjects: 9
Study 33982376 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Vancomycin (1000 mg metformin on days 16-19)
Number of subjects: 9
Study 33982592 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap syndrome (COPD and OSA)
Number of subjects: 0
Study 33982592 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD only
Number of subjects: 0
Study 33982592 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA only
Number of subjects: 0
Study 33982592 — intervention group
Group type: COMPARATOR
Intervention: Former smoker controls
Number of subjects: 0
Study 33982599 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT above upper reference limit
Number of subjects: 562
Study 33982599 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT quartiles comparison
Number of subjects: 562
Study 33982599 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 562
Study 33982909 — intervention group
Group type: EXPERIMENTAL
Intervention: Recipient body mass index at the time of liver biopsy
Number of subjects: 183
Study 33982909 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hepatitis C viral (HCV) infection
Number of subjects: 183
Study 33982909 — intervention group
Group type: COMPARATOR
Intervention: Donor steatosis
Number of subjects: 183
Study 33982909 — intervention group
Group type: COMPARATOR
Intervention: Donor and recipient metabolic syndrome features
Number of subjects: 183
Study 33982909 — intervention group
Group type: COMPARATOR
Intervention: Steatohepatitis
Number of subjects: 183
Study 33983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch (minimum 12 hours/day) during RT
Number of subjects: 10
Study 33983123 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 10
Study 33983131 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduce Sitting
Number of subjects: 405
Study 33983131 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase Transitions
Number of subjects: 405
Study 33983131 — intervention group
Group type: COMPARATOR
Intervention: Healthy Living (Control)
Number of subjects: 405
Study 33983492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment tumour-associated lymphocytes (TILs)
Number of subjects: 66
Study 33983492 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal lymphocytes (SLs)
Number of subjects: 66
Study 33983492 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant treatment
Number of subjects: 66
Study 33983498 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 200
Study 33983498 — intervention group
Group type: COMPARATOR
Intervention: Kalinox®
Number of subjects: 200
Study 33983671 — intervention group
Group type: EXPERIMENTAL
Intervention: DARC-positive ABMR
Number of subjects: 82
Study 33983671 — intervention group
Group type: EXPERIMENTAL
Intervention: DARC expression
Number of subjects: 82
Study 33983671 — intervention group
Group type: EXPERIMENTAL
Intervention: DARC immunohistochemistry
Number of subjects: 82
Study 33984029 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) patients
Number of subjects: 66
Study 33984029 — intervention group
Group type: COMPARATOR
Intervention: Healthy Older Volunteers (HOV)
Number of subjects: 66
Study 33984031 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of perioperative respiratory event (PRE)
Number of subjects: 312
Study 33984031 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of perioperative respiratory event (PRE) with unplanned admission
Number of subjects: 312
Study 33984031 — intervention group
Group type: COMPARATOR
Intervention: Presence of perioperative respiratory event (PRE) vs non-PRE
Number of subjects: 312
Study 33984519 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention to improve cancer surveillance and genetic counseling/testing access
Number of subjects: 0
Study 33984519 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy-focused genetic counseling approach
Number of subjects: 0
Study 33984519 — intervention group
Group type: COMPARATOR
Intervention: Usual care genetic counseling
Number of subjects: 0
Study 33984539 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ambulatory activity (AA) monitoring using accelerometric data from an insertable cardiac monitor.
Number of subjects: 186
Study 33984539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AA measurement.
Number of subjects: 186
Study 33984539 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up data for 45 participants with AA monitoring.
Number of subjects: 186
Study 33984539 — intervention group
Group type: EXPERIMENTAL
Intervention: AA during the early subacute period.
Number of subjects: 186
Study 33984672 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every 3 weeks
Number of subjects: 969
Study 33984675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal therapy (IT) with cytarabine or thiotepa
Number of subjects: 312
Study 33984675 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal therapy (IT) with methotrexate
Number of subjects: 312
Study 33984675 — intervention group
Group type: COMPARATOR
Intervention: Concomitant systemic therapy
Number of subjects: 312
Study 33984675 — intervention group
Group type: COMPARATOR
Intervention: Triple-negative subtype
Number of subjects: 312
Study 33984675 — intervention group
Group type: COMPARATOR
Intervention: Treatment line ≥3
Number of subjects: 312
Study 33984675 — intervention group
Group type: COMPARATOR
Intervention: ≥3 other metastatic sites
Number of subjects: 312
Study 33984675 — intervention group
Group type: COMPARATOR
Intervention: Curie score and Breast-graded prognostic assessment
Number of subjects: 312
Study 33984674 — intervention group
Group type: EXPERIMENTAL
Intervention: pN1mi (lymph node micro-metastases)
Number of subjects: 13773
Study 33984674 — intervention group
Group type: COMPARATOR
Intervention: pN1 (macro-metastases)
Number of subjects: 13773
Study 33984674 — intervention group
Group type: COMPARATOR
Intervention: pN1 = 1 (single macro-metastases)
Number of subjects: 13773
Study 33984674 — intervention group
Group type: COMPARATOR
Intervention: pN1 > 1 (multiple macro-metastases)
Number of subjects: 13773
Study 33984674 — intervention group
Group type: COMPARATOR
Intervention: pN1macro (in matched population analysis)
Number of subjects: 13773
Study 33984674 — intervention group
Group type: EXPERIMENTAL
Intervention: pN1mi (in matched population analysis)
Number of subjects: 13773
Study 33984846 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless measurements of vital signs
Number of subjects: 0
Study 33984846 — intervention group
Group type: COMPARATOR
Intervention: Standard measurements of vital signs
Number of subjects: 0
Study 33985406 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute pegboard and ring test (6PBRT)
Number of subjects: 34
Study 33985406 — intervention group
Group type: EXPERIMENTAL
Intervention: 6PBRT
Number of subjects: 34
Study 33985471 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal fruit and vegetable intake with baby lead weaning
Number of subjects: 144
Study 33985471 — intervention group
Group type: COMPARATOR
Intervention: Standard maternal fruit and vegetable intake with spoon feeding
Number of subjects: 144
Study 33985471 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diet and psychological features during pregnancy and breastfeeding
Number of subjects: 144
Study 33985471 — intervention group
Group type: EXPERIMENTAL
Intervention: Compositional and physicochemical analysis of milk during breastfeeding
Number of subjects: 144
Study 33985471 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's diet during weaning until 18 months of age
Number of subjects: 144
Study 33985574 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based informed consent forms for TKA and related anesthesia procedures
Number of subjects: 0
Study 33985574 — intervention group
Group type: COMPARATOR
Intervention: Standard consent forms
Number of subjects: 0
Study 33985811 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg for 2 cycles before surgery)
Number of subjects: 35
Study 33986031 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (initial therapy)
Number of subjects: 7438
Study 33986031 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic pulmonary angiography (diagnostic approach)
Number of subjects: 7438
Study 33986031 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 7438
Study 33986044 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced primary healthcare approaches including risk screening, patient engagement, shared decision making, and care coordination.
Number of subjects: 9
Study 33986057 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs), two doses with an intervention interval of 3 months.
Number of subjects: 40
Study 33986057 — intervention group
Group type: COMPARATOR
Intervention: Standard COPD medication treatment based on GOLD 2019 guidelines and Vietnam Ministry of Health protocol.
Number of subjects: 40
Study 33986123 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy
Number of subjects: 36
Study 33986123 — intervention group
Group type: COMPARATOR
Intervention: anti-PD-1 resistant tumors
Number of subjects: 36
Study 33986124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo armed T cells (EATs) using IgG-[L]-scFv-platformed bispecific antibodies (BsAb)
Number of subjects: 0
Study 33986124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo armed T cells (EATs) using γδ T cells
Number of subjects: 0
Study 33986124 — intervention group
Group type: COMPARATOR
Intervention: Separate BsAb and T cell injection
Number of subjects: 0
Study 33986124 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT therapy
Number of subjects: 0
Study 33986124 — intervention group
Group type: EXPERIMENTAL
Intervention: EATs after cryopreservation
Number of subjects: 0
Study 33986214 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fracture wounds
Number of subjects: 2500
Study 33986719 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0
Study 33986719 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33986914 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using low-cost VR goggles with a roller coaster application during the procedure
Number of subjects: 62
Study 33986914 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) during the procedure
Number of subjects: 62
Study 33986914 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 62
Study 33986914 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 62
Study 33987172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Magnitude High-Frequency Vibration (LMHFV)
Number of subjects: 972
Study 33987172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 972
Study 33987246 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Spontaneous Breathing Trial (SBT)
Number of subjects: 46
Study 33987279 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 33 °C for ≥72 h
Number of subjects: 192
Study 33987279 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 192
Study 33987279 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 192
Study 33987718 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare staff in COVID-19 units
Number of subjects: 971
Study 33987718 — intervention group
Group type: EXPERIMENTAL
Intervention: All healthcare staff
Number of subjects: 971
Study 33987718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-healthcare staff
Number of subjects: 971
Study 33987718 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 ICU staff
Number of subjects: 971
Study 33987718 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a COVID-19-confirmed household
Number of subjects: 971
Study 33987718 — intervention group
Group type: EXPERIMENTAL
Intervention: Working in a COVID-19 unit
Number of subjects: 971
Study 33987718 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with a confirmed COVID-19 coworker
Number of subjects: 971
Study 33987718 — intervention group
Group type: COMPARATOR
Intervention: Working in the COVID-19 ICU
Number of subjects: 971
Study 33988272 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing of monocytes
Number of subjects: 0
Study 33988508 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive GameSquad (AGS) intervention
Number of subjects: 23